GRI Bio Inc. (GRI NASDAQ) stock market data APIs
$2.2021
0.42(19.1%)
as of February 5, 2026
Try our APIs with
free plan!
GRI Bio Inc. Financial Data Overview
Price chart is built with
Anychart
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Prev. Close
2.2021
Open
2.6251
High
2.6332
Low
2.1965
52 wk Range
2.19-311.36
Market Cap
3 815 K
Shares Outstanding
1 445 K
EPS
-116.61
Beta
-1.232
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with GRI Bio Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GRI Bio Inc. data using free add-ons & libraries
Get GRI Bio Inc. Fundamental Data
GRI Bio Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -11 973 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-01-30
- EPS/Forecast: -29.26
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GRI Bio Inc. News
New
3 Promising Undervalued Small Caps In European Markets With Insider Buying
Amid renewed trade and geopolitical uncertainty, European markets have seen a downturn, with the pan-European STOXX Europe 600 Index ending 0.98% lower. Despite this challenging environment, business ...
GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF
Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio...
GRI Bio Announces Reverse Stock Split
GRI Bio, Inc. GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 26, 2026 LA JOLLA, CA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI...
European Undervalued Small Caps With Insider Action For January 2026
As the pan-European STOXX Europe 600 Index edges closer to record highs, buoyed by optimism about future earnings and economic prospects, small-cap stocks in Europe are capturing investor attention am...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
